Receptor-Ligand Binding Characteristics of KR-31064

KR-31064의 수용체-리간드 결합특성에 대한 연구

  • Lee, Sunghou (Dept. of Biomedical Technology, Sangmyung University)
  • 이승호 (상명대학교 천안캠퍼스 공과대학 의생명공학과)
  • Received : 2014.01.10
  • Accepted : 2014.01.21
  • Published : 2014.02.28

Abstract

KR-31064 was developed for the strong angiotensin II receptor antagonist among the one of pyridyl imidazol series compounds. To investigate the receptor-ligand binding characteristics of this nonpeptide antagonist, binding experiments were deployed in various conditions and ex vivo contractile responses were tested toward the standard compound, losartan. Receptor binding experiments with radiolabeled angiotensin II, the $IC_{50}$ value for KR-31064 resulted 0.67 nM without any activities toward type 2 angiotensin II receptor. The comparative potency against losartan was more than 18 fold and the specific activity in type 1 angiotensin II receptor was more than 10,000 fold comparing to the type 2 receptor. Scatchard analysis of saturation binding data showed KR-31064 acted on the receptor in a competitive mode. KR-31064 inhibited the contractile response derived by angiotensin II ($pK_B$: 9.86) similar to that of losartan with decreased maximum signals. As a potent and specific type 1 angiotensin II receptor antagonist, KR-31064 may have possibilities for the development of diagnostic ligands that can be used as tools for various biochemical research experiments and non-invasive diagnostics.

Acknowledgement

Supported by : 상명대학교

References

  1. Timmermans, P. B., Wong, P. C., Chiu, A. T., Herblin, W. F., Benfield, P., Carini, D. J., Lee, R. J., Wexler, R. R., Saye, J. A. and Smith, R. D. : Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 45, 205 (1993).
  2. Sever, P. S., Gradman, A. H. and Azizi, M. : Managing cardiovascular and renal risk: the potential of direct renin inhibition. J. Renin Angiotensin Aldosterone Syst. 10, 65 (2009). https://doi.org/10.1177/1470320309104662
  3. Williams, G. H. : Converting-enzyme inhibitors in the treatment of hypertension. N. Engl. J. Med. 319, 1517 (1988). https://doi.org/10.1056/NEJM198812083192305
  4. Coulter, D. M. and Edwards, I. R. : Cough associated with captopril and enalapril. Br. Med. J. (Clin. Res. Ed.) 294, 1521 (1987). https://doi.org/10.1136/bmj.294.6586.1521
  5. Roberts, J. R. and Wuerz, R. C. : Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema. Ann. Emerg. Med. 20, 555 (1991). https://doi.org/10.1016/S0196-0644(05)81616-6
  6. Griendling, K. K., Lassegue, B., Murphy, T. J. and Alexander, R. W. : Angiotensin II receptor pharmacology. Adv. Pharmacol. 28, 269 (1994). https://doi.org/10.1016/S1054-3589(08)60498-6
  7. Timmermans, P. B.: Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertension Res. 22, 147 (1999). https://doi.org/10.1291/hypres.22.147
  8. Wong, P. C., Price, W. A., Jr., Chiu, A. T., Duncia, J. V., Carini, D. J., Wexler, R. R., Johnson, A. L. and Timmermans, P. B. : In vivo pharmacology of DuP 753. Am. J. Hypertens. 4, 288S (1991). https://doi.org/10.1093/ajh/4.3.288
  9. Burnier, M. : Angiotensin II type 1 receptor blockers. Circulation 103, 904 (2001). https://doi.org/10.1161/01.CIR.103.6.904
  10. Simpson, K. L. and McClellan, K. J. : Losartan: a review of its use, with special focus on elderly patients. Drugs & Aging 16, 227 (2000). https://doi.org/10.2165/00002512-200016030-00006
  11. Iimori, H., Hashizume, Y., Sasaki, M., Kajiwara, Y., Sugimoto, Y., Sugiyama, Y., Watanabe, Y. and Senda, M. : First automatic radiosynthesis of 11C labeled Telmisartan using a multipurpose synthesizer for clinical research use. Ann. Nucl. Med. 25, 333 (2011). https://doi.org/10.1007/s12149-011-0466-2
  12. Mathews, W. B., Yoo, S. E., Lee, S. H., Scheffel, U., Rauseo, P. A., Zober, T. G., Gocco, G., Sandberg, K., Ravert, H. T., Dannals, R. F. and Szabo, Z. : A novel radioligand for imaging the AT1 angiotensin receptor with PET. Nucl. Med. Biol. 31, 571 (2004). https://doi.org/10.1016/j.nucmedbio.2003.10.014
  13. Shimizu, K., Takashima, T., Yamane, T., Sasaki, M., Kageyama, H., Hashizume, Y., Maeda, K., Sugiyama, Y., Watanabe, Y. and Senda, M. : Whole-body distribution and radiation dosimetry of [11C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3. Nucl. Med. Biol. 39, 847 (2012). https://doi.org/10.1016/j.nucmedbio.2012.01.008
  14. Xia, J., Seckin, E., Xiang, Y., Vranesic, M., Mathews, W. B., Hong, K., Bluemke, D. A., Lerman, L. O. and Szabo, Z. : Positron-emission tomography imaging of the angiotensin II subtype 1 receptor in swine renal artery stenosis. Hypertension 51, 466 (2008). https://doi.org/10.1161/HYPERTENSIONAHA.107.102715
  15. Han, J., Park, S. J., Thu, V. T., Lee, S. R., Long, L. T., Kim, H. K., Kim, N., Park, S. W., Jeon, E. S., Kim, E. J., Yoon, C. H., Cho, G. Y. and Choi, D. J. : Effects of the novel angiotensin II receptor type I antagonist, fimasartan on myocardial ischemia/ reperfusion injury. Intl. J. of Cardiol. 168, 2851 (2013). https://doi.org/10.1016/j.ijcard.2013.03.151
  16. Lee, S. : Characterization of angiotensin II antagonism displayed by KR-31081, a novel nonpeptide AT1 receptor antagonist. J. Korea Academia-Industrial Cooperation Soc. 10, 2997 (2009). https://doi.org/10.5762/KAIS.2009.10.10.2997
  17. Cheng, Y. and Prusoff, W. H. : Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099 (1973). https://doi.org/10.1016/0006-2952(73)90196-2
  18. Wienen, W., Hauel, N., Van Meel, J. C., Narr, B., Ries, U. and Entzeroth, M. : Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br. J. Pharmacol. 110, 245 (1993). https://doi.org/10.1111/j.1476-5381.1993.tb13800.x
  19. Hilditch, A., Hunt, A. A., Travers, A., Polley, J., Drew, G. M., Middlemiss, D., Judd, D. B., Ross, B. C. and Robertson, M. J. : Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist. J. Pharmacol. Exp. Ther. 272, 750 (1995).
  20. Wong, P. C., Price, W. A., Jr., Chiu, A. T., Duncia, J. V., Carini, D. J., Wexler, R. R., Johnson, A. L. and Timmermans, P. B. : Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther. 255, 211 (1990).
  21. Panek, R. L., Lu, G. H., Overhiser, R. W., Major, T. C., Hodges, J. C. and Taylor, D. G. : Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism. J. Pharmacol. Exp. Ther. 273, 753 (1995).
  22. Timmermans, P. B. and Smith, R. D. : Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur. Heart J. 15 Suppl D, 79 (1994). https://doi.org/10.1093/eurheartj/15.suppl_D.79
  23. Bond, R. A., Ornstein, A. G. and Clarke, D. E. : Unsurmountable antagonism to 5-hydroxytryptamine in rat kidney results from pseudoirreversible inhibition rather than multiple receptors or allosteric receptor modulation. J. Pharmacol. Exp. Ther. 249, 401 (1989).